top of page

Upcoming webinar

Screenshot 2025-12-27 023955.png
April webinar (4).png
Screenshot 2025-12-27 023955.png

Join a practical, clinically focused webinar dedicated to optimizing care for patients with platinum-resistant recurrent ovarian cancer, a setting characterized by rapidly evolving definitions, therapeutic options, and clinical evidence.

 

This session will be led by Robert Coleman and is designed to equip clinicians with the tools to interpret and apply emerging evidence, integrate current regulatory decisions, and strategically position novel and investigational therapies in everyday practice.

 

Learning Objectives

At the end of this session, participants will be able to:

  • Define and apply the current taxonomy for platinum-resistant recurrent ovarian cancer and explain how the timing of resistance affects eligibility, endpoints, and interpretation of clinical trial data.

  • Translate recent FDA decisions and label updates into practical, multidisciplinary care pathways by selecting appropriate candidates, identifying required testing and biomarkers, and implementing safe administration and toxicity-mitigation practices (e.g., ADC-specific and immune-related adverse events), including drug–drug interaction considerations.

  • Critically appraise the contemporary investigational landscape (e.g., ADCs, immune combinations, DDR and kinase inhibitors) to propose evidence-based sequencing strategies and strategic considerations for patient care.

Coleman Headshot for Programs 200.jpg

Robert L. Coleman, MD, FACOG, FACS

Chief Medical Officer

Vaniam Group

Conflict of interest 

Dr. Coleman completed his Obstetrics & Gynecology residency at Northwestern University Medical Center in Chicago, Illinois, and completed his fellowship at The University of Texas MD Anderson Cancer Center in 1993. From 1993-1996, he served as Assistant Professor at Creighton University followed by service as Vice-Chairman, Department of Obstetrics and Gynecology at the University of Texas, Southwestern Medical Center. Dr. Coleman joined as Faculty at MD Anderson Cancer center in 2004 and served as Professor and Executive Director for Cancer Network Research, holding the Ann Rife Cox Chair in Gynecology. In March 2020, he joined US Oncology Research (USOR) as Chief Scientific Officer and served briefly as Chief Medical Officer for Sarah Cannon Research Institute (SCRI). He practices at Texas Oncology, US Oncology Network and currently serves as Chief Medical officer for Vaniam Group. He also serves as Vice President, GOG Foundation and is Special Advisor to the President for GOG Partners. Dr. Coleman has authored or coauthored over 800 scientific publications, including over 470 peer-reviewed articles, along with numerous book chapters, monographs, invited articles, and textbooks. He was the 2019 APGO-CREOG awardee for Excellence in Teaching. He served as President of SGO (2015-2016) and President of IGCS (2020-2022). He was recently inducted into MJH Life Sciences™ 2020 class of “Giants in Cancer Care®.”

Screenshot 2025-12-27 023955.png

Scientific Committee

Past Webinars

Immunothérapie dans le cancer de l’endomètre
01:22:45
Webinaire_Chimiotherapie
01:30:56
Webinaire_RECIST_Chenard-Poirier_RGOQ
52:37
Webinaire_RECIST_Rioux_RGOQ
47:08
Webinaire : Cancer de l’ovaire récidivant
01:34:56
Webinaire sur l'obésité
02:04:10
Introduction
28:15
Webinaire sur l'immunotherapie - Cas 1
13:42
Webinaire sur l'immunotherapie - Cas 2
14:30
Webinaire sur l'immunotherapie - Cas 3
17:56
_Les critères RECIST webinar (1).png

Join us for a practical, case-based webinar led by experts Dr. Maxime Rioux and Dr. Maxime Chénard-Poirier, designed to strengthen your knowledge and clinical skills in applying the RECIST criteria (Response Evaluation Criteria in Solid Tumors). This session addresses a significant practice gap in the consistent use of RECIST and aims to support better decision-making in oncology.

 

Learning objectives

By the end of this presentation, participants will be able to:

  • Familiarize yourself with the RECIST criteria.

  • Describe several examples of RECIST application in routine clinical practice.

 

This activity is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification (MOC) Program of the Royal College of Physicians and Surgeons of Canada, as well as a recognized professional development activity (Category A) as defined by the Collège des médecins du Québec. This activity has been approved by the Continuing Professional Development (CPD) Directorate of the Fédération des médecins spécialistes du Québec.

You may claim a maximum of 1.5 hours under Section 1 / recognized professional development activity (Category A). Participants should claim only the number of hours that corresponds to the duration of their participation.

IMG_6353.jpeg

Maxime Rioux

Radiologist

CHU de Québec

Conflict of interest 

Dr. Maxime Rioux is a diagnostic radiologist in the Department of Medicine at Université Laval, with specialized expertise in abdominal and pelvic imaging. He plays a key role in multidisciplinary oncology care by providing precise interpretation of imaging studies to support informed clinical decision-making.

Maxime Chénard-Poirier, MD, FRCPC

Medical Oncologist and Hematologist

CHU de Québec - Université Laval
Conflict of interest

Dr. Maxime Chénard-Poirier is a Clinical Professor in the Department of Medicine at the Faculty of Medicine, Université Laval, and an Associate Researcher in the Oncology Axis at the Hôtel-Dieu de Québec (HEJ) research centre

Scientific Committee

This content was developed by the RGOQ with an unrestricted grant from the following sponsor: Merck Canada. The sponsor had no role in the development of the content, the selection of topics, or the choice of speakers. The views expressed in this presentation are solely those of the authors/speakers: Dr. Maxime Rioux and Dr. Maxime Chénard-Poirier.

Vincent Castonguay WEBINAR (6).png

Discover practical tips and cutting-edge information with Dr. Vincent Castonguay (Université Laval), as we explore how combining first-line chemotherapy and immunotherapy can transform outcomes for patients with recurrent or advanced endometrial cancer.

Learning objectives

By the end of this presentation, participants will be able to:

  • Evaluate the role of first-line chemotherapy combined with immunotherapy in the management of recurrent or advanced endometrial cancer, integrating current evidence and clinical trial results to guide therapeutic decisions.

  • Analyze the mechanisms of action and synergistic effects of immunotherapy when combined with chemotherapy, with a focus on their application in gynecologic oncology.

  • Apply updated protocols and guidelines for the treatment of recurrent or advanced endometrial cancer in clinical practice, taking into account patient-specific factors and multidisciplinary collaboration with pathologists and oncologists.

  • Discuss innovative approaches in gynecologic oncology, including the integration of molecular pathology and immunotherapy, to improve diagnostic and therapeutic strategies through interdisciplinary collaboration.

  • Identify potential challenges and adverse effects associated with combined chemotherapy and immunotherapy regimens, developing strategies to minimize risks and optimize outcomes for patients.

This activity is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification (MOC) Program of the Royal College of Physicians and Surgeons of Canada, as well as a recognized professional development activity (Category A) as defined by the Collège des médecins du Québec. This activity has been approved by the Continuing Professional Development (CPD) Directorate of the Fédération des médecins spécialistes du Québec.

You may claim a maximum of 1.5 hours under Section 1 / recognized professional development activity (Category A). Participants should claim only the number of hours that corresponds to the duration of their participation.

Vincent Castonguay_web.jpg

Vincent Castonguay

Hematologist-oncologist

CHU-de-Québec

Conflict of interest 

Vincent Castonguay has been a hematologist-oncologist at the CHU de Québec since 2012. He completed his residency in hematology and oncology at Université Laval, followed by a fellowship at the Princess Margaret Hospital in Toronto specializing in gynecologic malignancies and phase I clinical trials. His main clinical and research interests are in uro-oncology and gynecologic oncology. He served as Director of the Medical Oncology Program at Université Laval from 2014 to 2023 and is currently Co-Chief of the Hematology-Oncology Department at the CHU de Québec.

This content was developed by the RGOQ with an unrestricted grant from the following sponsor: Merck Canada. The sponsor had no role in the development of the content, the selection of topics, or the choice of speaker. The views expressed in this presentation are solely those of the author/speaker: Dr. Vincent Castonguay.

Scientific Committee

Webinar resource

This webinar resource provides a concise overview of ovarian cancer, highlighting key facts on risk factors, symptoms, diagnosis, and treatment approaches. It also explains the concept of platinum sensitivity versus resistance to guide therapeutic decisions. Designed to support clinical discussions and continuing education, this resource offers clear, evidence-based insights.

4.png
bottom of page